ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2703

Reduction in Matrix Metalloproteinase-1 and -2 Secretion from Fibroblast-like Synoviocytes after Induction of Adipogenesis By a Natural Peroxisome Proliferator-Activated Receptor Gamma Ligand, Arterpilin-C

Eiji Sugiyama1, Satoshi Yamasaki1 and Je-Tae Woo2,3, 1Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 2Department of Biological Chemistry, Chubu University, Aichi, Japan, 3JT WOO, Okinawa Research Center Co., Ltd, Okiawa, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: adipose tissue, Mesenchymal stem cells, PPAR-gamma, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibroblast-like synoviocytes (FLS) play important roles in rheumatoid arthritis (RA) by producing matrix metalloproteinase (MMP) and cytokines, and hence, these cells are a therapeutic target. Another unique characteristic of FLS is their ability to differentiate into mesenchymal multilineage cells, such as osteoblasts, chondrocytes, and adipocytes. Based on this characteristic, we proposed that the induction of adipogenesis in FLS would ameliorate RA activity by reducing cytokine and protease secretion from the cell. Thus, in this study, we treated FLS with plant-derived natural PPARγ ligands—arterpilin-C —to induce adipogenesis in FLS and evaluated the MMP secretion from FLS following adipogenesis induction.

Methods: The FLS derived from RA patients (Articular Engineering, USA) were maintained in Dulbecco’s Modification of Eagles Medium with 10% fetal bovine serum. To induce adipogenesis via FLS, we added arterpilin-C to the culture medium in the presence or absence of dexamethasone. Lipid deposition in FLS was examined by using Oil red O or LipidTOX™ (Molecular Probes, USA) staining. To confirm adipogenic differentiation, we used anti-fatty acid binding protein 4 antibodies for immunostaining. A quantitative polymerase chain reaction using SYBR Green was performed to determine the expression levels of the transcripts.

Results: Droplets were observed in the cytoplasm of FLS after a 3-week culture with arterpilin-C (30 µM) in the presence of dexamethasone. Oil red O or LipidTOX staining confirmed adipogenesis by FLS. The expression of FABP4, an adipocyte-specific protein, was also noted in the cells with droplets by immunostaining. However, adipogenesis by arterpilin-C was achieved only in the presence of dexamethasone in a dose-dependent manner. The minimum dexamethasone concentration required for adipogenesis induction by arterpilin-C in FLS was 10-7 M. PPARγ protein expression was clearly enhanced in FLS treated with a dexamethasone concentration of 10-7M. Moreover, the MMP1 and MMP2 mRNA expressions were lower in the FLS following adipogenesis induced by arterpilin-C, compared to the FLS treated only with dexamethasone.

Conclusion: These data suggest that the natural PPARγ ligands, arterpilin-C , can be used to induce adipogenesis in FLS. Importantly, the expressions of MMP1 and MMP2 were significantly reduced in FLS following adipogenesis induced by these natural PPARγ ligands. Since these proteinases are important in RA disease progression, induction of adipogenesis in FLS may contribute to inhibiting joint destruction in RA.


Disclosure: E. Sugiyama, Santen Pharmaceutical Co.,Ltd, Astellas Pharma Inc., Pfizer Inc., Chugai Pharmaceutical Co.,Ltd., AbbVie GK (AbbVie Godo Kaisha), TEIJIN PHARMA LIMITED., Mitsubishi Tanabe Pharma Corporation, Eisai. Co.,Ltd., Taisho Toyama Pharmaceutical Co.,Ltd., Kissei, 2; S. Yamasaki, Eli Lilly K.K., 2; J. T. Woo, JT WOO, Okinawa Research Center Co., Ltd, 4.

To cite this abstract in AMA style:

Sugiyama E, Yamasaki S, Woo JT. Reduction in Matrix Metalloproteinase-1 and -2 Secretion from Fibroblast-like Synoviocytes after Induction of Adipogenesis By a Natural Peroxisome Proliferator-Activated Receptor Gamma Ligand, Arterpilin-C [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/reduction-in-matrix-metalloproteinase-1-and-2-secretion-from-fibroblast-like-synoviocytes-after-induction-of-adipogenesis-by-a-natural-peroxisome-proliferator-activated-receptor-gamma-ligand-arterpi/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-in-matrix-metalloproteinase-1-and-2-secretion-from-fibroblast-like-synoviocytes-after-induction-of-adipogenesis-by-a-natural-peroxisome-proliferator-activated-receptor-gamma-ligand-arterpi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology